Goldman Sachs Group Inc Protalix Bio Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 92,424 shares of PLX stock, worth $97,045. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,424
Previous 104,476
11.54%
Holding current value
$97,045
Previous $185,000
37.3%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PLX
# of Institutions
66Shares Held
9.27MCall Options Held
40.6KPut Options Held
10.1K-
Black Rock Inc. New York, NY3.31MShares$3.48 Million0.0% of portfolio
-
State Street Corp Boston, MA827KShares$867,9100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny825KShares$865,9350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA754KShares$791,8150.0% of portfolio
-
Gsa Capital Partners LLP London, X0494KShares$518,2490.05% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $52.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...